AZN vs PFE
AstraZeneca PLC and Pfizer Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | AZN | PFE |
|---|---|---|
| Revenue | $58.7B | $62.6B |
| Net income | $10.2B | $7.8B |
| Gross margin | 81.9% | 74.3% |
| Net margin | 17.4% | 12.5% |
| Return on equity | 22.9% | 8.9% |
| Diluted EPS | $6.54 | $1.36 |
| Dividend / share | $3.13 | $1.72 |
| Payout ratio | 48.6% | · |
| Free cash flow | $11.8B | $9.1B |
| Equity | $48.7B | $86.5B |
| Net debt / equity | 0.49× | 0.73× |
| Current ratio | 0.94× | 1.16× |
| Revenue CAGR 5y | 17.2% | 8.5% |
| Profit CAGR 5y | 26.2% | −3.2% |
AZN and PFE book revenue within 15% of each other, and keeps more of each dollar of revenue as profit (17.4% against 12.5%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | AZN | PFE |
|---|---|---|
| FY2025 | $58.7B | $62.6B |
| FY2024 | $54.1B | $63.6B |
| FY2023 | $45.8B | $59.6B |
| FY2022 | $44.4B | $101.2B |
| FY2021 | $37.4B | $81.3B |
| FY2020 | $26.6B | $41.7B |
| FY2019 | $24.4B | $40.9B |
| FY2018 | $22.1B | $40.8B |
| FY2017 | $22.5B | $52.5B |
| FY2016 | $23.0B | $52.8B |
Bottom line
| Fiscal year | AZN | PFE |
|---|---|---|
| FY2025 | $10.2B | $7.8B |
| FY2024 | $7.0B | $8.0B |
| FY2023 | $6.0B | $2.1B |
| FY2022 | $3.3B | $31.4B |
| FY2021 | $112.0M | $22.0B |
| FY2020 | $3.2B | $9.2B |
| FY2019 | $1.3B | $16.0B |
| FY2018 | $2.2B | $11.2B |
| FY2017 | $3.0B | $21.3B |
| FY2016 | $3.5B | $7.2B |
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$3,840,000,000 | PFE |
| FY2024 | −$9,554,000,000 | PFE |
| FY2023 | −$13,742,000,000 | PFE |
| FY2022 | −$56,824,000,000 | PFE |
| FY2021 | −$43,871,000,000 | PFE |
| FY2020 | −$15,034,000,000 | PFE |
| FY2019 | −$16,521,000,000 | PFE |
| FY2018 | −$18,735,000,000 | PFE |
| FY2017 | −$30,081,000,000 | PFE |
| FY2016 | −$29,822,000,000 | PFE |
| FY2015 | −$24,143,000,000 | PFE |
PFE has reported the higher revenue in every one of these 11 fiscal years. The gap has narrowed since the earliest year compared.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
11 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +4.9 pp | AZN |
| FY2024 | +0.4 pp | AZN |
| FY2023 | +9.4 pp | AZN |
| FY2022 | −23.6 pp | PFE |
| FY2021 | −26.8 pp | PFE |
| FY2020 | −10.3 pp | PFE |
| FY2019 | −34.2 pp | PFE |
| FY2018 | −18.1 pp | PFE |
| FY2017 | −27.9 pp | PFE |
| FY2016 | +1.1 pp | AZN |
| FY2015 | −2.9 pp | PFE |
The higher net margin has changed hands between AZN and PFE over this period.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PFE's net margin has been more volatile than AZN's over the 11 comparable fiscal years — 11.4 percentage points of standard deviation against 4.6.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between AZN and PFE over these 11 fiscal years — AZN led in 4 and PFE in 7.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
PFE's return on equity has been more volatile than AZN's over the 11 comparable fiscal years — 10.9 percentage points of standard deviation against 6.4.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between AZN and PFE over these 11 fiscal years — AZN led in 6 and PFE in 5.
11 of 19 comparable fiscal years — a year missing data on either side is not counted.